Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 123-127

  Husain, Hatim ^a,b   Savage, William ^b   Grossman, Stuart A ^a,b   Ye, Xiaobu ^a,b   Burger, Peter C ^b   Everett, Allen ^b   Bettegowda, Chetan ^a,b   Diaz, Luis A ^b   Blair, Cherie ^b   Romans, Katharine E ^b   Holdhoff, Matthias ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Circulating tumor marker; Glial fibrillary acidic protein; Glioblastoma; Glioma

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; ELECTROCHEMISTRY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSTOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864285431     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0874-8     Document Type: Article

References (13)

1. D Brandsma L Stalpers W Taal P Sminia MJ van den Bent 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 10.1016/S1470-2045(08)70125-6 18452856 10.1016/S1470-2045(08)70125-6 (Pubitemid 351597795)
2. AA Brandes E Franceschi A Tosoni V Blatt A Pession G Tallini R Bertorelle S Bartolini F Calbucci A Andreoli, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844 10.1200/JCO.2007.14.8163
3. M Holdhoff SA Grossman 2011 Controversies in the adjuvant therapy of high-grade gliomas Oncologist 16 351 358 10.1634/theoncologist.2010-0335 21339260 10.1634/theoncologist.2010-0335 1:CAS:528:DC%2BC3MXhtlSktr3L
4. PP Zheng WC Hop PA Sillevis Smitt MJ van den Bent CJ Avezaat TM Luider JM Kros 2005 Low-molecular weight caldesmon as a potential serum marker for glioma Clin Cancer Res 11 4388 4392 10.1158/1078-0432.CCR-04-2512 15958622 10.1158/1078-0432.CCR-04-2512 1:CAS:528:DC%2BD2MXltFeksr8%3D (Pubitemid 40825628)
5. ME Fukuda Y Iwadate T Machida T Hiwasa Y Nimura Y Nagai M Takiguchi H Tanzawa A Yamaura N Seki 2005 Cathepsin D is a potential serum marker for poor prognosis in glioma patients Cancer Res 65 5190 5194 10.1158/0008-5472.CAN-04- 4134 15958563 10.1158/0008-5472.CAN-04-4134 1:CAS:528:DC%2BD2MXltFemurg%3D (Pubitemid 40827328)
6. A Hormigo B Gu S Karimi E Riedel KS Panageas MA Edgar MK Tanwar JS Rao M Fleisher LM DeAngelis, et al. 2006 YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Clin Cancer Res 12 5698 5704 10.1158/1078-0432.CCR-06-0181 17020973 10.1158/1078-0432.CCR-06- 0181 1:CAS:528:DC%2BD28XhtVartbrE (Pubitemid 44629598)
7. MT Wunderlich CW Wallesch M Goertler 2006 Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke Eur J Neurol 13 1118 1123 10.1111/j.1468-1331.2006.01435.x 16987165 10.1111/j.1468-1331.2006.01435.x 1:STN:280:DC%2BD28rmt1Snsg%3D%3D (Pubitemid 44434318)
8. MM Bembea W Savage JJ Strouse JM Schwartz E Graham CB Thompson A Everett 2011 Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation Pediatr Crit Care Med 12 572 579 10.1097/PCC.0b013e3181fe3ec7 21057367 10.1097/PCC.0b013e3181fe3ec7
9. PE Vos M van Gils T Beems C Zimmerman MM Verbeek 2006 Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity Eur J Neurol 13 632 638 10.1111/j.1468-1331.2006.01332.x 16796588 10.1111/j.1468-1331.2006.01332.x 1:STN:280:DC%2BD28zotFagtw%3D%3D (Pubitemid 43873636)
10. PE Vos B Jacobs TM Andriessen KJ Lamers GF Borm T Beems M Edwards CF Rosmalen JL Vissers 2010 GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study Neurology 75 1786 1793 10.1212/WNL.0b013e3181fd62d2 21079180 10.1212/WNL.0b013e3181fd62d2 1:CAS:528:DC%2BC3cXhsVans7jN
11. WJ Savage E Barron-Casella Z Fu P Dulloor L Williams BJ Crain DA White JM Jennings JE Van Eyk MR Debaun, et al. 2011 Plasma glial fibrillary acidic protein levels in children with sickle cell disease Am J Hematol 86 427 429 10.1002/ajh.21995;10.1002/ajh.21995 21523806 10.1002/ajh.21995 1:CAS:528:DC%2BC3MXltFyjtbs%3D
12. CS Jung C Foerch A Schanzer A Heck KH Plate V Seifert H Steinmetz A Raabe M Sitzer 2007 Serum GFAP is a diagnostic marker for glioblastoma multiforme Brain 130 3336 3341 10.1093/brain/awm263 17998256 10.1093/brain/awm263 1:STN:280:DC%2BD2sjitVKisg%3D%3D (Pubitemid 350209077)
13. T Brommeland L Rosengren S Fridlund R Hennig V Isaksen 2007 Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas Acta Neurol Scand 116 380 384 10.1111/j.1600-0404.2007.00889.x 17986096 10.1111/j.1600-0404.2007.00889.x 1:CAS:528:DC%2BD2sXhsVyjsb7E (Pubitemid 350045499)